Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

NovaBay Pharmaceuticals (NBY) Leases (2019 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Leases for 11 consecutive years, with $189000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Leases fell 81.86% to $189000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $189000.0, a 81.86% decrease, with the full-year FY2024 number at $955000.0, down 26.31% from a year prior.
  • Leases was $189000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $306000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $2.3 million in Q1 2022 to a low of $170000.0 in Q3 2021.
  • A 5-year average of $1.1 million and a median of $1.1 million in 2024 define the central range for Leases.
  • Peak YoY movement for Leases: soared 1039.41% in 2022, then tumbled 81.86% in 2025.
  • NovaBay Pharmaceuticals' Leases stood at $411000.0 in 2021, then surged by 345.5% to $1.8 million in 2022, then decreased by 29.22% to $1.3 million in 2023, then fell by 26.31% to $955000.0 in 2024, then tumbled by 80.21% to $189000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Leases are $189000.0 (Q3 2025), $306000.0 (Q2 2025), and $343000.0 (Q1 2025).